Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 2, 2002, Pages 75-80

  Nabhan, Chadi ^a   Rosen, Steven T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD20 ANTIGEN; CD52 ANTIGEN; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; IMMUNOMODULATION; LYMPHOCYTOPENIA; NAUSEA; PRIORITY JOURNAL;

EID: 0036179094     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30150     Document Type: Conference Paper

References (39)

1. Cancer statistics, 2000
2. Clinical staging of chronic lymphocytic leukemia
3. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia
4. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
5. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
6. Continuous cultures of fused cells secreting antibody of predefined specificity
7. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
8. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
9. Monoclonal antibodies: Basic principles, radioisotope conjugates
10. Levels of expression of CD19 and CD20 in chronic B cell leukaemias
11. The Campath-1 antigen (CDw52)
12. Primary structure of CD52
13. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
14. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
15. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
16. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
17. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
18. Phase II study of rituximab (Rituxan) in patients with previously untreated low-grade or follicular non-Hodgkin's lymphoma
19. Toxicity and efficacy of the anti-CD20 antibody rituximab (Rituxan) in patients with B-cell chronic lymphocytic leukemia: A phase I/II study
20. Rituximab dose-escalation trial in chronic lymphocytic leukemia
21. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
22. Rituximab therapy of B-cell neoplasms
23. Fludarabine and cyclophosphamide combined with Rituxan (FCR) is a potent cytoreductive regimen as initial therapy of chronic lymphocytic leukemia
24. Rituximab/cyclophosphamide/dexamethasone combination highly effective in autoimmune hemolytic anemia associated with chronic lymphocytic leukemia
25. Effects of Campath-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
26. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H
27. Reshaping human antibodies for therapy
28. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro
29. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody
30. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
31. Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
32. Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia refractory to fludarabine
33. Campath-1H therapy in 29 patients with refractory CLL: True complete remission is an attainable goal
34. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia
35. Subcutaneous Campath-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia
36. Immunosuppressive toxicity of Campath-1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma
37. Preclinical and phase I and II trials of rituximab
38. Phase I study of combining rituximab and campath-1H in patients with relapsed or refractory chronic lymphocytic leukemia